Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study Using Chemoimmunotherapy With Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC)

NCT06064097 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT06064097
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06064097 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study Using Chemoimmunotherapy With Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Recruiting
Start date
June 25, 2024
Completion date
March 31, 2027
Enrollment
50 (estimated)
Sites
86

Conditions

As the registry lists them; a condition with its own page is linked.

stage ii nasopharyngeal carcinoma ajcc v8, stage iii nasopharyngeal carcinoma ajcc v8, stage iv nasopharyngeal carcinoma ajcc v8